PCVX vs SYRE
Vaxcyte, Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
PCVX
Vaxcyte, Inc.
66
Insufficient Data
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | PCVX | SYRE |
|---|
| AI Score |
66
|
67
|
| Price |
$59.22
|
$102.72
|
| P/E Ratio |
-7.75×
|
-52.69×
|
| ROE |
-28.5%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
0.0%
|
| Debt / Equity |
0.04×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.6
|
53.3
|
| Beta |
1.21
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for PCVX versus SYRE.
SYRE leads by 1 points.
SYRE scores 67/100 (Insufficient Data) versus PCVX at 66/100 (Insufficient Data).
PCVX Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical